Medical University of Graz

medunigraz.at

Total trials

460

Active

97

Phase 3

23

Total enrollment

9,252,365

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 10 of 10 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
L-ornithine L-aspartate1
Poractant alfa (Curosurf®) - 1-minute administration1
Poractant alfa (Curosurf®) - 5-minute administration1
Amoxicillin1
Cholecalciferol5
Fecal microbiota transplantation1
Insect Venom2
Biomarker Monitoring1
all approved chemotherapeutic agents from second line1
Hepatect CP 50 I.E./ml infusion solution1

Next readouts

  • 2024-07-23
  • 2025-12
  • 2025-12
  • 2026-03
  • 2026-03-01
  • 2026-06
  • 2027-03
  • 2027-03
  • 2028-07-01

Top conditions

  • Pulmonary Hypertension16
  • Type 1 Diabetes12
  • Psoriasis9
  • Type 2 Diabetes9
  • Obesity9
  • Liver Cirrhosis8
  • Vitamin D Deficiency8
  • Polymorphic Light Eruption6

Frequently asked questions about Medical University of Graz

How many clinical trials does Medical University of Graz have on ClinicalTrials.gov?
Medical University of Graz is listed as the lead sponsor on 460 clinical trials in ClinicalTrials.gov, 97 of which are currently active (recruiting, enrolling, or ongoing).
How many of Medical University of Graz's trials are in Phase 3?
23 of Medical University of Graz's trials are in Phase 3, spread across 10 active drug programs.
What therapeutic areas does Medical University of Graz focus on?
Medical University of Graz's most-studied conditions on ClinicalTrials.gov are Pulmonary Hypertension, Type 1 Diabetes, Psoriasis, Type 2 Diabetes, Obesity.
When are Medical University of Graz's next clinical trial readouts?
Medical University of Graz has 9 upcoming primary-completion readouts tracked here; the soonest is “Effect of L-ornithine-L-aspertate (LOLA) on the Gut Microbiome”, expected around 2024-07-23.